These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 10404890)

  • 1. Summary and conclusion. Animal sera, animal sera derivatives and substitutes used in the manufacture of pharmaceuticals.
    Castle P; Robertson JS
    Dev Biol Stand; 1999; 99():191-6. PubMed ID: 10404890
    [No Abstract]   [Full Text] [Related]  

  • 2. Risks of virus transmission associated with animal sera or substitutes and methods of control.
    Eloit M
    Dev Biol Stand; 1999; 99():9-16. PubMed ID: 10404870
    [No Abstract]   [Full Text] [Related]  

  • 3. Bovine polyomavirus, a frequent contaminant of calf sera.
    van der Noordaa J; Sol CJ; Schuurman R
    Dev Biol Stand; 1999; 99():45-7. PubMed ID: 10404875
    [No Abstract]   [Full Text] [Related]  

  • 4. Detecting viruses in sera: methods used and their merits.
    Jennings A
    Dev Biol Stand; 1999; 99():51-9. PubMed ID: 10404876
    [No Abstract]   [Full Text] [Related]  

  • 5. An animal origin perspective of common constituents of serum-free medium formulations.
    Jayme DW
    Dev Biol Stand; 1999; 99():181-7. PubMed ID: 10404889
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Quality control of bovine serum used for vaccine production.
    Mareschal JC
    Dev Biol Stand; 1999; 99():61-8. PubMed ID: 10404877
    [No Abstract]   [Full Text] [Related]  

  • 7. Safety issues of animal products used in serum-free media.
    Merten OW
    Dev Biol Stand; 1999; 99():167-80. PubMed ID: 10404888
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Why do we still use serum in the production of biopharmaceuticals?
    Shah G
    Dev Biol Stand; 1999; 99():17-22. PubMed ID: 10404871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An overview of animal cell substrates for biological products.
    Petricciani J; Sheets R
    Biologicals; 2008 Nov; 36(6):359-62. PubMed ID: 18674929
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Elimination of serum from cell culture medium.
    Lubiniecki AS
    Dev Biol Stand; 1999; 99():153-6. PubMed ID: 10404886
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bovine serum: reducing the variables through the use of donor herds.
    Rolleston WB
    Dev Biol Stand; 1999; 99():79-86. PubMed ID: 10404879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Control of manufacture--the EC point of view.
    Meyer P
    Dev Biol Stand; 1992; 79():159-62. PubMed ID: 1286750
    [No Abstract]   [Full Text] [Related]  

  • 13. Current good tissue practice for human cell, tissue, and cellular and tissue-based product establishments; inspection and enforcement. Final rule.
    Food and Drug Administration, HHS
    Fed Regist; 2004 Nov; 69(226):68611-88. PubMed ID: 15562555
    [TBL] [Abstract][Full Text] [Related]  

  • 14. WHO requirements for the use of animal cells as in vitro substrates for the production of biologicals (requirements for biological substances No 50).
    Dev Biol Stand; 1998; 93():141-71. PubMed ID: 9737395
    [No Abstract]   [Full Text] [Related]  

  • 15. Quality of biotechnological products: viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():177-201. PubMed ID: 9737396
    [No Abstract]   [Full Text] [Related]  

  • 16. Serum supply: policies and controls operating in New Zealand.
    Shailer C; Corrin K
    Dev Biol Stand; 1999; 99():71-7. PubMed ID: 10404878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The development, benefits and disadvantages of serum-free media.
    Froud SJ
    Dev Biol Stand; 1999; 99():157-66. PubMed ID: 10404887
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal-free culture process for manufacture of viral vaccines: process validation and regulatory perspectives.
    Pierard I; Mareschal JC; Gonze MM; Duchêne M
    Dev Biol (Basel); 2006; 123():283-90; discussion 291-308. PubMed ID: 16566454
    [No Abstract]   [Full Text] [Related]  

  • 19. [Problems raising from the control of biological products employed in medicine. Control of sera, vaccines, and biological products in France].
    Desbordes J
    Ann Ist Super Sanita; 1969; 5(3-4):218-81. PubMed ID: 16089166
    [No Abstract]   [Full Text] [Related]  

  • 20. Quality of biotechnological products: derivation and characterisation of cell substrates used for production of biotechnological/biological products. ICH Harmonised Tripartite Guideline.
    Dev Biol Stand; 1998; 93():223-34. PubMed ID: 9737399
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.